[PDF][PDF] Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a …

TM Beer, CW Ryan, PM Venner, DP Petrylak… - Journal of Clinical …, 2007 - academia.edu
TM Beer, CW Ryan, PM Venner, DP Petrylak, GS Chatta, JD Ruether, CH Redfern…
Journal of Clinical Oncology, 2007academia.edu
Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With
Placebo Plus Docetaxel in Androgen-Independ Page 1 Double-Blinded Randomized Study
of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent
Prostate Cancer: A Report From the ASCENT Investigators Tomasz M. Beer, Christopher W.
Ryan, Peter M. Venner, Daniel P. Petrylak, Gurkamal S. Chatta, J. Dean Ruether, Charles H.
Redfern, Louis Fehrenbacher, Mansoor N. Saleh, David M. Waterhouse, Michael A …
Purpose
To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel.
academia.edu